This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-13 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Studies comparing the efficacy of PPIs indicate that esomeprazole and tenatoprazole have stronger acid suppression, with a longer period of intragastric pH (pH > 4). Studies of the effect of tenatoprazole on acid secretion in in vivo animal models, such as pylorus-ligated rats and acute gastric fistula rats, demonstrated a 2- to 4-fold more potent inhibitory activity compared with omeprazole. A more potent inhibitory activity was also shown in several models of induced gastric lesions. In Asian as well as Caucasian healthy subjects, tenatoprazole exhibited a seven-fold longer half-life than the existing H+/K+ ATPase inhibitors. It is thus hypothesized that a longer half-life results in a more prolonged inhibition of gastric acid secretion, especially during the night. A strong relationship has been stated between the degree and duration of gastric acid inhibition, as measured by monitoring of the 24-hour intragastric pH in pharmacodynamic studies, and the rate of healing and symptom relief reported. A clinical study showed that nocturnal acid breakthrough duration was significantly shorter for 40 mg of tenatoprazole than for 40 mg of esomeprazole, with the conclusion that tenatoprazole was significantly more potent than esomeprazole during the night. Although, the therapeutic relevance of this pharmacological advantage deserves further study. PPIs have been used successfully in triple-therapy regiments with clarithromycin and amoxicillin for the eradication of Helicobacter pylori with no significant difference between different PPI-based regimens.
Pharmacy is the science and practice of dispensing, preparing, reviewing safety and efficacy, monitoring, discovering, producing, and consulting about medications, aiming to ensure the safe, effective, and affordable use of medicines. It is an interdisciplinary science as it links health sciences, pharmaceutical sciences, and natural sciences with the humanities. The professional practice is clinically oriented, with most drugs now being manufactured by pharmaceutical industries and prescribed in the medical setting. Based on the setting, pharmacy practice is either classified as community or institutional pharmacy. Providing direct patient care is considered clinical pharmacy, mainly practiced in institutions like hospitals, long-term care facilities, hospice, ambulatory clinics, or psychiatric hospitals. However, more clinical application are becoming important in the community setting to combat barriers to accessing healthcare (e.g., immunizations, point of care testing, oral contraceptive prescribing, administering injectable therapies, suggesting OTC products, or prescribing under Physician backed protocols). The scope of pharmacy practice includes more traditional roles such as dispensing and compounding of medications based on compendiums, like the USP. It also includes more modern services related to health care including clinical services involving medical guideline appropriateness, reviewing medications for safety and efficacy, and providing drug information with patient counselling.
=== Efficacy === Efficacy is the ability of a treatment or intervention to produce its intended effect under controlled conditions. It can be influenced by factors such as dosage, patient characteristics, disease severity, and treatment adherence.
Sources: en.wikipedia.org
== Services == Eucalyptus provides telehealth consultations, e-prescriptions, and medication delivery through partner pharmacies. Services are delivered through specialised brands targeting specific health concerns:
Solanum pimpinellifolium, commonly known as the currant tomato or pimp, is a wild species of tomato native to Ecuador and Peru but naturalized elsewhere, such as the Galápagos Islands. Its small fruits are edible, and it is commonly grown in gardens as an heirloom tomato, although it is considered to be wild rather than domesticated as is the commonly cultivated tomato species Solanum lycopersicum. Its genome was sequenced in 2012.
=== Proteins === In the secondary structure of proteins, hydrogen bonds form between the backbone oxygens and amide hydrogens. When the spacing of the amino acid residues participating in a hydrogen bond occurs regularly between positions i and i + 4, an alpha helix is formed. When the spacing is less, between positions i and i + 3, then a 310 helix is formed. When two strands are joined by hydrogen bonds involving alternating residues on each participating strand, a beta sheet is formed. Hydrogen bonds also play a part in forming the tertiary structure of protein through interaction of R-groups. (See also protein folding). Bifurcated H-bond systems are common in alpha-helical transmembrane proteins between the backbone amide C=O of residue i as the H-bond acceptor and two H-bond donors from residue i + 4: the backbone amide N−H and a side-chain hydroxyl or thiol H+. The energy preference of the bifurcated H-bond hydroxyl or thiol system is −14 or 167 kJ/mol (−3.4 or 40 kcal/mol) respectively. This type of bifurcated H-bond provides an intrahelical H-bonding partner for polar side-chains, such as serine, threonine, and cysteine within the hydrophobic membrane environments. The role of hydrogen bonds in protein folding has also been linked to osmolyte-induced protein stabilization. Protective osmolytes, such as trehalose and sorbitol, shift the protein folding equilibrium toward the folded state, in a concentration dependent manner.
== See also == Analytical chemistry Chromatography Gas chromatography–mass spectrometry Gas chromatography-olfactometry High-performance liquid chromatography Inverse gas chromatography Proton transfer reaction mass spectrometry Secondary electrospray ionization Selected ion flow tube mass spectrometry Standard addition Thin layer chromatography Unresolved complex mixture
Sources: en.wikipedia.org
=== Common complications === Hemolytic crisis, with more pronounced jaundice due to accelerated hemolysis (may be precipitated by infection). Aplastic crisis with dramatic fall in hemoglobin level and (reticulocyte count)-decompensation, usually due to maturation arrest and often associated with megaloblastic changes; may be precipitated by infection, such as influenza, notably with parvovirus B19. Folate deficiency caused by increased bone marrow requirement. Pigmented gallstones occur in approximately half of untreated patients. Increased hemolysis of red blood cells leads to increased bilirubin levels, because bilirubin is a breakdown product of heme. The high levels of bilirubin must be excreted into the bile by the liver, which may cause the formation of a pigmented gallstone, which is composed of calcium bilirubinate. Since these stones contain high levels of calcium carbonates and phosphate, they are radiopaque and are visible on x-ray. Hyperglycemia with concomitant low hemoglobin A1C levels. Hemoglobin A1C (glycated hemoglobin) is a test for determining the average blood glucose levels over an extended period of time, and is often used to evaluate glucose control in diabetics. The hemoglobin A1C levels are abnormally low because the life span of the red blood cells is decreased - providing less time for the non-enzymatic glycosylation of hemoglobin. Thus, even with high overall blood sugar, the A1C will be lower than expected. Iron overload. Leg ulcer. Deep vein thrombosis (DVT). Cardiovascular disease.
== Applications == Structural biologists have made significant contributions towards understanding the molecular components and mechanisms underlying human diseases. For example, cryo-EM and ssNMR have been used to study the aggregation of amyloid fibrils, which are associated with Alzheimer's disease, Parkinson's disease, and type II diabetes. In addition to amyloid proteins, scientists have used cryo-EM to produce high resolution models of tau filaments in the brain of Alzheimer's patients which may help develop better treatments in the future. Structural biology tools can also be used to explain interactions between pathogens and hosts. For example, structural biology tools have enabled virologists to understand how the HIV envelope allows the virus to evade human immune responses. Structural biology is also an important component of drug discovery. Scientists can identify targets using genomics, study those targets using structural biology, and develop drugs that are suited for those targets. Specifically, ligand-NMR, mass spectrometry, and X-ray crystallography are commonly used techniques in the drug discovery process. For example, researchers have used structural biology to better understand Met, a protein encoded by a protooncogene that is an important drug target in cancer. Similar research has been conducted for HIV targets to treat people with AIDS. Researchers are also developing new antimicrobials for mycobacterial infections using structure-driven drug discovery.
Groups such as the Bat Conservation International aim to increase awareness of bats' ecological roles and the environmental threats they face. This group called for Bat Appreciation Week from 24–31 October every year to promote awareness of the ecological importance of bats. In the United Kingdom, all bats are protected under the Wildlife and Countryside Acts, and disturbing a bat or its roost can be punished with a heavy fine. In Sarawak, Malaysia, "all bats" are protected under the Wildlife Protection Ordinance 1998, but species such as the hairless bat (Cheiromeles torquatus) are still eaten by the local communities. Humans have caused the extinction of several species of bat in modern history, the most recent being the Christmas Island pipistrelle (Pipistrellus murrayi), which was declared extinct in 2009. Many people put up bat houses to attract bats. The 1991 University of Florida bat house is the largest occupied artificial roost in the world, with around 450,000–500,000 residents. In Britain, thick-walled and partly underground World War II pillboxes have been converted to make roosts for bats, and purpose-built 'bat bridges' are occasionally built to mitigate damage to habitat from roads or other developments. Cave gates are sometimes installed to limit human entry into caves with sensitive or endangered bat species. The gates are designed not to limit the airflow and thus to maintain the cave's micro-ecosystem. In the United States, 35 of the 47 bat species roost on human-made structures, while 14 of them use bat houses.
Keratoconus Global Award (2009) for his work on CXL technology. Carl Camras Award 2014 for translational research (Association for Research in Vision and Ophthalmology [ARVO]) The 2014 IIRSI Gold Medal for his efforts in introducing CXL into clinical ophthalmology Member of The Ophthalmologist Power List Top 100 (2014, 2016, 2018, 2020, and 2023) Casebeer Award (2014) of the International Society for Refractive Surgery. The 2016 El-Maghraby International Award for his contributions to ophthalmology The 2016 Gold Medal of SAMIR for his pioneering work on corneal cross-linking Elected as an honorary member of Hungary's SHIOL (Societas Hungarica Ad Implantandam Oculi Lenticulam) in 2016 Appointed FARVO (Fellow of ARVO) in 2019 Additionally, in 2012, Hafezi and his colleague, Dr. Olivier Richoz, won the University of Geneva's INNOGAP award for the development of a disposable medical device (the C-Eye device) for performing PACK-CXL. Hafezi is one of the most cited ophthalmologists of his generation, with a h index of 45 and a total more than 7,700 citations in the scientific literature.
Stoess, on the other hand, had reestablished relations with Eastman Kodak in the United States and was bringing large quantities of much-needed foreign exchange to Germany. After World War II, Paul Koepff Jr. became managing director of the Stoess company in Eberbach. In 1949, he built up a gelatin capsule factory there. In the course of the decades, DGF AG bought various factories worldwide. In 1965, it was taken over by the "Chem. Werke Stoess" in Heidelberg. In that year Heinrich Koepff took over the majority of shares of the Göppingen plant and through his marriage to the granddaughter of the company founder, Gerda Stoess, the companies merged. In 1972, the association traded under the name DGF Stoess & Co. GmbH. In 1989, the company was converted into a public limited company. The gelatin production division was renamed the Gelita Group in 1999. In 2005, all entities started to sell gelatine under the brand name Gelita.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.